

# Age-Cohort Models for Recurrent Events in Longitudinal Studies

H.M. Hudson<sup>1,2</sup>, M.B. Barton<sup>3</sup>, G. Delaney<sup>3</sup>, Z. Hao<sup>1,3</sup>, S. Allen<sup>3</sup>

<sup>1</sup> Dept. Statistics, Macquarie University, Australia

<sup>2</sup> Faculty of Medicine, University of Sydney

<sup>3</sup> Faculty of Medicine, University of New South Wales

Malcolm.Hudson@mq.edu.au

1 June, 2011

Aims. . . . .	2
LMCTC . . . . .	3
Analysis Frameworks. . . . .	5
MSM . . . . .	6
Single cohort. . . . .	8
Methods. . . . .	9
Results. . . . .	10
Findings I. . . . .	12
Theorem . . . . .	13
Risk factors . . . . .	14
Transition risk factors. . . . .	15
Covariates . . . . .	16
Survival . . . . .	17
RT factors . . . . .	18
Breast . . . . .	19
Findings II . . . . .	21
References . . . . .	22

## Aims

### 1. Compare different marginal methods for counting recurrent events

- recurrent events ('retreatments') ended by a terminal event ('death')
- variety of marginal estimates of mean function

### 2. Case study of cancer *retreatments* in LMCTC

- Liverpool and Macarthur Cancer Therapy Centres (LMCTC) database
- our goal, estimation of **mean retreatments** and risk factor effects **following initial RT** for Breast and Lung cancer

ISCB Ottawa, 2011

Hudson – 2 / 22

## Background

### • Survival with intermediate events

- recurrent events ('retreatments') ended by a terminal event ('death')
- focus on the **retreatment process** rather than **survival**

### • Patterns of Retreatment by Radiotherapy in LMCTC

- 8300 cancer patients accrued following **initial RT** in the period 1997-2006
- **follow-up to end of 2010** for further *retreatments* and deaths
- supplemented by NSW State Cancer Registry mortality data
- descriptive analysis<sup>a</sup> available

---

<sup>a</sup>Barton et al, Clinical Oncology 23 (2011) 10–18

ISCB Ottawa, 2011

Hudson – 3 / 22

## LMCTC analysis

- **First-event analysis options**

- Complication-free survival time (i.e. time to first event)  
deaths may dominate K-M plots
- Competing risk analysis: CIF of time to first retreatment  
directed at outcome of interest

- **Multiple recurrence analysis:**

- **first-event unsuitable** for comprehensive summaries and cost implications
- summaries of **number of events** do not address variations in survival  $\Rightarrow$  **uninterpretable**
- summaries of **events-per-p.y.** don't distinguish terminators (end-of-study vs. death)

ISCB Ottawa, 2011

Hudson – 4 / 22

## Frameworks for Analysis

- **Intensity based conditional methods**

- Probability of new event may depend on previous event history
- Models valid under *adaptive censoring* (censoring conditionally independent of events)
- Problems in interpreting effects of treatments or baseline covariates in trials

- **Marginal methods:**

- Marginal features: event rates or cumulative mean; time to a specified event; gap times.
- Many well developed methods valid under *independent censoring*
- Cumulative mean can be estimated by methods of Cook and Lawless<sup>a</sup>.


---

<sup>a</sup>Cook, Lawless, et al JASA 2009

ISCB Ottawa, 2011

Hudson – 5 / 22

## MSM diagram: LMCTC



State transition diagram and statistics.

Number of events from each node's person years (p.y.'s)

- ⇒ *ratio obsd retreatments to deaths* increase from 1:3 to 1:1 after more RTs  
 ⇒ *event rates per p.y.* increase from **1 in 10** to **1** after two or more RTs

ISCB Ottawa, 2011

Hudson – 6 / 22

## Multi-state recurrence model

- Conditional model but interpretable (marginal features)
  - MSM of recurrences easily adapted for terminal events [Figure]
  - cumulative mean function (**CMF**)
  - robust estimates of **state occupancy** probabilities<sup>a</sup>
- ⇒ robust estimation of the *marginal* distribution of the cumulative number of events over time:
- probabilities of 0, 1, 2, ... retreatments before time t (allowing for death terminating)

<sup>a</sup>Aalen et al 2001, Datta & Satten, 2001, Gunnes et al 2007

ISCB Ottawa, 2011

Hudson – 7 / 22

## Homogeneous cohort

- **Target**

- $P(N(t) \geq 1)$  (**prevalence**)
- Mean number of events by time  $t$  (**CMF**)

- **End of at risk interval**

- ends on administrative censoring (EOF date)
- Methods differ: **end f/u** on **death** preceeding EOF?
  - Cook and Lawless marginal methods – YES
  - Multi-state models (Aalen-Johansen) – YES
  - MCUT (life table) models – NO  $\Rightarrow$  simply **ignore deaths!**

ISCB Ottawa, 2011

Hudson – 8 / 22

## Methods

### Events and follow-up

Method	Events data	Intervals	sensor time	Reference
MCUT	retreatments	RT0-RTk, RT0-eof	sensor at eof	KP, ZM
C-L	retreatments and death	RT0-RTk, RT0-death	death (or eof)	CL 4.1
Pepe2	retreatments and death	RT0-RTk, RT0-death	death (or eof)	CL 4.2
N-A	death/RT (composite)	RT0 -'event'	eof	*
A-J	retreatments and death	inter-events-death	death (or eof)	CL 4.3

eof = End date of follow-up

RT0 = Date of initial radiotherapy

RTk = Date of k-th retreatment

CL = Cook, Lawless et al, JASA, 2009

KP = Kalbfleisch & Prentice (text)

ZM = Zhang-Salomons and Mackillop, Comp.Meth.Prog.Biomed., 2008

ISCB Ottawa, 2011

Hudson – 9 / 22

## Results – All pts

Cumulative mean numbers: retreatments per 1000 RT patients

Method	Year			
	2	4	8	12
MCUT	159	197	233	253
C-L	159	197	234	255
Pepe	159	197	233	254
Composite	159	197	233	255
A-J	159	197	234	253

All methods show a high level of agreement

ISCB Ottawa, 2011

Hudson – 10 / 22

## Results – Subgroups

Cumulative mean numbers: retreatments per 1000 RT patients

LUNG CANCER					
Method	Year				
	2	4	8	12	
MCUT	298	318	324	329	
C-L	297	318	325	329	
Pepe	298	318	324	328	
Composite	298	319	325	329	
A-J	298	319	326	330	
BREAST CANCER					
Method	Year				
	2	4	8	12	
MCUT	83	146	218	248	
C-L	83	148	<b>228</b>	<b>261</b>	
Pepe	83	146	219	250	
Composite	83	148	<b>228</b>	<b>259</b>	
A-J	83	148	<b>225</b>	<b>257</b>	

ISCB Ottawa, 2011

Hudson – 11 / 22

## Findings for LMCTC

### Concerning methods

- Since all patients experience at least 4 years follow up, all methods provide the same mean number of events up to time  $t = 4$ .
- Thereafter, some estimates differ.
- But differences are small, for mean retreatments to  $t = 8$  and  $t = 12$  years
- Even for Breast Cancer, with continuing incidence of new retreatments to 12+ years.
- **Is follow-up of deaths necessary in this context?**

ISCB Ottawa, 2011

Hudson – 12 / 22

## Multiple Cohorts

**Theorem 1 (Deaths in cohort analysis)** Assume longitudinal data is available on **first recurrence**

- homogeneous patient cohorts  $1, 2, \dots, I$  :
- a common entry date in each cohort;
- a common exit date (other than death);
- cohort  $i$  has a pre-specified length of follow up  $\tau_i$ ;
- this **administrative censoring** is the only source of censoring.

Then the **empirical CIF** of time from entry to **first recurrence**, allowing for death as competing cause, is the **proportion** of first recurrences **observed before time  $t$**  on study, and is **independent of times of death** up to the maximum time of follow-up.

ISCB Ottawa, 2011

Hudson – 13 / 22

## Factors affecting the CMF of retreatments

### Data

- all methods are informed by dates of **initial RT** and **retreatment** events.
- standard method utilise date of **death** (terminal event).
- CMF may depend on risk factors for competing events: retreatment(s) and death


### LMCTC

- Breast and Lung cancer patients differ in retreatment timings (CMF)
- Now explore effects of fixed covariates **age** and date of initial RT (**dst** or 'cohort')
- **Is follow-up of deaths necessary in this context?**

ISCB Ottawa, 2011

Hudson – 14 / 22

## MSM diagram: Liverpool Hospital



The first competing events after initial RT are first retreatment (RT1) and death.

ISCB Ottawa, 2011

Hudson – 15 / 22



## Results – Risk factors

Coefficients<sup>a</sup> of Age\* and Year of Entry (start date of RT)



LUNG CANCER				
Outcome	age	P	start	P
Survival	.0058	0.02	.0244	0.04
Survival as 1st event	.0137	<0.001	.0265	0.06
Time to 1st retreatment (MCUT)	-.0376	<0.001	.0203	NS
Time to 1st retreatment (CR)	-.0316	<0.001	.0387	0.06
Time to 1st retreatment (FG)	-.0316	<0.001	.0387	0.06
Gap to 2nd/later retreat (CR)	.0085	NS	-0.038	NS
BREAST CANCER				
Outcome	age	P	start	P
Survival	.0289	<0.001	-.0525	0.001
Survival as 1st event	.0459	<0.001	-.0919	<0.001
Time to 1st retreatment (MCUT)	-.0049	NS	-.0054	NS
Time to 1st retreatment (CR)	-.0017	NS	-.0107	NS
Time to 1st retreatment (FG)	-.0048	NS	-.0103	NS
Gap to 2nd/later retreat (CR)	-.0155	0.05	.0072	NS

<sup>a</sup>Anderson-Gill via coxph

ISCB Ottawa, 2011

Hudson – 16 / 22

## Factors affecting survival in Lung Cancer





Linear age effect: shorter *survival* at older ages in lung cancer patients

ISCB Ottawa, 2011

Hudson – 17 / 22

## Factors affecting retreatment incidence in Lung Cancer





Anderson-Gill model of time to retreatment, censoring death.

Older Lung Cancer patients **not utilising retreatment as early** as others in Lung Cancer, when death has not intervened

ISCB Ottawa, 2011

Hudson – 18 / 22

## Factors affecting survival in Breast Cancer



In Breast Cancer *survival*, age effect is non-monotonic, hazard bottoms at age 50 and accelerates beyond 70.



Large monotonic hazard reduction with increasing calendar date of first RT.

Both age and cohort effects are strongly significant.

ISCB Ottawa, 2011

Hudson – 19 / 22

## Factors affecting retreatment incidence in Breast Cancer



**Younger and older** Breast Cancer patients utilise **retreatment earlier**

ISCB Ottawa, 2011

Hudson – 20 / 22

## Findings – covariates

Methods and data required

- **Each** marginal method has a corresponding **model** for hazards of events (conditional, CR, etc).
- Competing risks model separates **interpretation of effects** on recurrent events and terminal event.
- Some factors affect death and event incidence (sometimes in opposite directions).
- Useful to **integrate effects** on risk of death with effects on retreatment incidence (given alive). **Can we understand the net effect of a covariate on the CMF?** Answer depends on method.

LMCTC findings concerning methods

- **Coefficients**, their **SEs** and **P-values** differ little between **MCUT (ignoring deaths)** and **competing risk analysis** (retreatment 1 versus death).
- Follow-up of *deaths* **does not add much** to findings in LMCTC data.
- We found **no evidence of efficiency gain** in estimating CMFs and risk factor effects using death data.

ISCB Ottawa, 2011

Hudson – 21 / 22

## References

Barton, Hudson, Delaney et al, Clinical Oncology 23 (2011) 10–18  
Cook & Lawless, The Statistical Analysis of Recurrent Events, Springer, 2007  
Cook, Lawless et al JASA 2009  
Fine, Gray JASA, 94: 496-509, 1999  
Geskus, Biometrics 67, 39–49, 2011  
Gooley, Statistics in Medicine, 18, 695-706, 1999  
Kalbfleisch & Prentice, The Statistical Analysis of Failure Time Data, Wiley, 2002  
Lawless, Statistical Models and Methods for Lifetime Data, 2003  
Therneau & Grambsch, Modeling Survival Data: Extending the Cox Model, Springer, 2000